Onur Baser, MS, PhD; Mady Chalk, PhD; Richard Rawson, PhD; and David R. Gastfriend, MD
Alcohol consumption is the third leading actual cause of death in the United States1
; however, among the top 25 diseases, patients with alcohol-use disorders are least likely to receive care that is based upon evidence-based practice.2
The overall cost to the United States for alcohol-related illness was estimated at $184 billion in 19983
; payers spend an estimated $9.7 billion annually on direct treatment of these disorders.4
Historically, over 70% of these costs has been spent by public systems4
; however, this proportion is expected to increasingly shift to the private pay sector in coming years as a result of federal parity and health care legislative reform. With a national prevalence of alcohol dependence of 3.8%, or 7.9 million adults,5
these morbidity, mortality, and cost burdens are driving efforts to develop the most clinically effective and resource-efficient evidence-based treatments possible.
The dominant mode of treatment of alcohol dependence is psychosocial treatment or counseling, and several models have shown evidence for effectiveness.6
Although 4 medications have been approved by the US Food and Drug Administration (FDA) for the treatment of alcohol dependence, there is little adoption of these agents.7,8
Survey results published in 2007 reported that pharmacotherapies for substance-use disorders (SUDs) were offered in less than 25% of public and private specialty treatment programs7
and a 2007 study reported that SUD medications comprised less than 1% of all SUD treatment costs.8
Nevertheless, the National Institute on Alcohol Abuse and Alcoholism has issued recommendations stating that medications are “helpful to patients in reducing drinking, reducing relapse to heavy drinking, achieving and maintaining abstinence, or a combination of these effects” and clinicians should “consider adding medication whenever [they] are treating someone with active alcohol dependence.”6
There are multiple reasons why medication-assisted treatment (MAT) for alcohol dependence is not widely used, including long-standing traditions rooted in the mutual help movement, but adoption of MAT is also predicated on concerns about poor patient adherence to medication, modest efficacy, and poor costeffectiveness.9-11
Retrospective insurance database studies of oral medications have reported that 50% of patients fail to obtain their first refill,12,13
and refill rates are worse for alcoholism medications than for statins and psychiatric medications.14
Clinical trials have found that medication adherence is crucial to efficacy.15
Medication adherence in substance-dependence treatment has been a priority concern of the National Institutes of Health for over 3 decades.16
In 2006, the FDA approved the first extended-release formulation for the treatment of alcohol dependence, extended-release naltrexone (XR-NTX), which was designed to address the challenge of adherence through a once-monthly injection.17
Of the 4 agents FDA-approved for the treatment of alcohol dependence studied in a retrospective claims analysis of commercial insureds, XR-NTX was associated with reduced estimated charges and utilization of inpatient detoxification days and alcoholism-related inpatient days, compared with all 3 oral agents (ie, oral naltrexone, disulfiram, and acamprosate calcium).18
Given the importance of alcohol dependence treatment for public health and healthcare cost containment, the present study was designed to extend current knowledge of real-world effectiveness with alcohol dependence treatments, including treatment with no medication, any approved medication, and among the approved medications, treatment with each specific agent. This study sought to examine a larger cohort of insured patients treated with XR-NTX than previously studied, and to determine a comprehensive range of healthcare utilization and actual expended healthcare costs for each treatment category.MethodsData Sources and Study Population
This was a retrospective database analysis conducted using commercial enrollees from a large US health plan affiliated with i3 Innovus and the PharMetrics Integrated Database from 2005 to 2009. These databases included medical and pharmacy claims from all available healthcare sites (inpatient, hospital outpatient, emergency department [ED], physician’s office, and surgery center) for virtually all types of provided services, including specialty, preventive office-based treatments, and retail and mail order pharmacy claims.
For the comparison of the “no medication” group to the “any medication” group, patients were required have at least 1 claim for alcohol dependence (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
, code 303.xx) during the pre- or post-index period, have an alcohol use disorder diagnosis pre-index, and have at least 6 months of continuous enrollment pre-index and 6 months post-index. The earliest pharmacy claim for alcohol medication was set as the index date for the any medication group. The index date was defined as the first medical claim for a nonpharmacologic treatment such as a detoxification facility claim, a substance abuse treatment facility claim, or a substance abuse counseling claim. Patients in the nonpharmacologic substance group had no prescription fills for alcoholism medication while patients in the any medication group had at least 1 fill for any of the 4 alcoholism medications. Patients with liver failure during the pre-index period were excluded. Furthermore, patients were excluded if they had claims for pharmacological treatment in the month prior to the index date (with the exception of the XR-NTX group, because this group was occasionally required to demonstrate prior oral medication failure). These inclusion/exclusion criteria led to a final sample of 20,670 patients in the no medication group and 15,502 patients in the any medication group. Figure 1
presents the sample sizes after applying the inclusion/exclusion criteria.
PDF is available on the last page.